A detailed history of Rhumbline Advisers transactions in Lucid Diagnostics Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 66,129 shares of LUCD stock, worth $71,419. This represents 0.0% of its overall portfolio holdings.

Number of Shares
66,129
Previous 63,016 4.94%
Holding current value
$71,419
Previous $72,000 8.33%
% of portfolio
0.0%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 06, 2025

BUY
$0.97 - $1.48 $3,019 - $4,607
3,113 Added 4.94%
66,129 $66,000
Q2 2025

Aug 12, 2025

BUY
$1.09 - $1.65 $68,687 - $103,976
63,016 New
63,016 $72,000

Others Institutions Holding LUCD

About Lucid Diagnostics Inc.


  • Ticker LUCD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 38,568,500
  • Market Cap $41.7M
  • Description
  • Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarc...
More about LUCD
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.